However, vaccination with soluble ovalbumin protein linked to antibodies directed to the DCIR2 surface receptor of the CD8- subset of DCs induced effective CD8+T cell immunity against the B16-OVA melanoma tumor after injection of the conjugate in vivo (35). The gene discussed is CD8A; the disease is neoplasm.